MX2023004008A - Derivados de tetrazol como inhibidores de trpa1. - Google Patents
Derivados de tetrazol como inhibidores de trpa1.Info
- Publication number
- MX2023004008A MX2023004008A MX2023004008A MX2023004008A MX2023004008A MX 2023004008 A MX2023004008 A MX 2023004008A MX 2023004008 A MX2023004008 A MX 2023004008A MX 2023004008 A MX2023004008 A MX 2023004008A MX 2023004008 A MX2023004008 A MX 2023004008A
- Authority
- MX
- Mexico
- Prior art keywords
- tetrazole derivatives
- trpa1
- trpa1 inhibitors
- inhibitors
- inhibition
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003536 tetrazoles Chemical class 0.000 title abstract 2
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title 1
- 102100031366 Ankyrin-1 Human genes 0.000 abstract 1
- 101710191059 Ankyrin-1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente descripción proporciona ciertos derivados de tetrazol que son inhibidores del receptor de potencial transitorio anquirina 1 (TRPA1) y, por lo tanto, son útiles para el tratamiento de enfermedades tratables mediante la inhibición de TRPA1. También se proporcionan composiciones farmacéuticas que los contienen y procesos para preparar dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20201708 | 2020-10-14 | ||
| PCT/EP2021/078295 WO2022079092A1 (en) | 2020-10-14 | 2021-10-13 | Tetrazole derivatives as trpa1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004008A true MX2023004008A (es) | 2023-04-26 |
Family
ID=72885375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004008A MX2023004008A (es) | 2020-10-14 | 2021-10-13 | Derivados de tetrazol como inhibidores de trpa1. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11661427B2 (es) |
| EP (1) | EP4228756B1 (es) |
| JP (1) | JP7565439B2 (es) |
| KR (1) | KR20230087531A (es) |
| CN (1) | CN116249535A (es) |
| AU (1) | AU2021363101A1 (es) |
| CA (1) | CA3193606A1 (es) |
| CL (1) | CL2023000837A1 (es) |
| IL (1) | IL301706A (es) |
| MX (1) | MX2023004008A (es) |
| TW (1) | TW202229292A (es) |
| WO (1) | WO2022079092A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202229293A (zh) * | 2020-10-14 | 2022-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為trpa1抑制劑之四唑衍生物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1013705A2 (pt) | 2009-03-23 | 2016-04-05 | Glenmark Pharmaceuticals Sa | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| CN111201234A (zh) | 2017-07-17 | 2020-05-26 | 南京瑞捷医药科技有限公司 | 新型化合物及其作为acc抑制剂的用途 |
-
2021
- 2021-10-13 IL IL301706A patent/IL301706A/en unknown
- 2021-10-13 AU AU2021363101A patent/AU2021363101A1/en active Pending
- 2021-10-13 EP EP21787477.5A patent/EP4228756B1/en active Active
- 2021-10-13 CA CA3193606A patent/CA3193606A1/en active Pending
- 2021-10-13 US US17/500,133 patent/US11661427B2/en active Active
- 2021-10-13 MX MX2023004008A patent/MX2023004008A/es unknown
- 2021-10-13 JP JP2023522545A patent/JP7565439B2/ja active Active
- 2021-10-13 WO PCT/EP2021/078295 patent/WO2022079092A1/en active Application Filing
- 2021-10-13 TW TW110137890A patent/TW202229292A/zh unknown
- 2021-10-13 KR KR1020237015753A patent/KR20230087531A/ko unknown
- 2021-10-13 CN CN202180066927.3A patent/CN116249535A/zh active Pending
-
2023
- 2023-03-23 CL CL2023000837A patent/CL2023000837A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3193606A1 (en) | 2022-04-21 |
| EP4228756A1 (en) | 2023-08-23 |
| IL301706A (en) | 2023-05-01 |
| KR20230087531A (ko) | 2023-06-16 |
| CN116249535A (zh) | 2023-06-09 |
| US11661427B2 (en) | 2023-05-30 |
| EP4228756B1 (en) | 2024-06-12 |
| US20220112202A1 (en) | 2022-04-14 |
| TW202229292A (zh) | 2022-08-01 |
| AU2021363101A1 (en) | 2023-03-23 |
| JP7565439B2 (ja) | 2024-10-10 |
| JP2023545159A (ja) | 2023-10-26 |
| CL2023000837A1 (es) | 2023-11-24 |
| WO2022079092A1 (en) | 2022-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550604A1 (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| MX2021012549A (es) | Derivados de tetrahidro-1h-ciclopenta[cd]indeno como inhibidores del factor inducible por hipoxia-2(alfa). | |
| ZA202200519B (en) | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents | |
| PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
| SA522441965B1 (ar) | Trpa1 مشتقات تترازول كمثبطات لـ | |
| MX2020009228A (es) | Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma. | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| MX2023011829A (es) | Derivados de uracilo como inhibidores de trpa1. | |
| MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
| SA522441973B1 (ar) | Trpa1 مشتقات تترازول كمثبطات لـ | |
| MX2023014784A (es) | Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| PH12021550258A1 (en) | Cdk8/19 inhibitors | |
| SA523440367B1 (ar) | مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1 | |
| ZA202100955B (en) | Thrombin inhibitors, formulations, and uses thereof | |
| MX2021008748A (es) | Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias. | |
| MX2023011830A (es) | Derivados de 3h,4h-tieno [2,3-d]pirimidin-4-ona como inhibidores de trpa1. | |
| SA522431667B1 (ar) | مركبات بيبريدينيل- ميثيل-بورين أمين في صورة مثبطات nsd2 وعوامل مضادة للسرطان | |
| EA202192859A1 (ru) | ПРОИЗВОДНЫЕ ТЕТРАГИДРО-1Н-ЦИКЛОПЕНТА[cd]ИНДЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА-2 (АЛЬФА), ИНДУЦИРУЕМОГО ГИПОКСИЕЙ |